TOP STORY
Scientists Find Key to Hormone-Resistant Prostate Tumors
Researchers working with mice believe they have uncovered a mechanism by which the secondary prostate tumors gain their resistance — a finding that eventually might help prolong the lives of men with prostate cancer. [Press release from BusinessWeek discussing online prepublication in Nature]
|
|
CURRENT PUBLICATIONS
LABORATORY RESEARCH
B Cell-Derived Lymphotoxin Promotes Castration-Resistant Prostate Cancer
Here researchers show that androgen ablation causes infiltration of regressing androgen-dependent tumours with leukocytes, including B cells, in which IKK-beta activation results in production of cytokines that activate IKK-alpha and STAT3 in prostate cancer cells to enhance hormone-free survival. [Nature]
A Novel Type of Cellular Senescence That Can Be Enhanced in Mouse Models and Human Tumor Xenografts to Suppress Prostate Tumorigenesis
The data identifies a type of cellular senescence that can be triggered in nonproliferating cells in the absence of DNA damage, which researchers believe will be useful for developing a “pro-senescence” approach for cancer prevention and therapy. [J Clin Invest]
Matrix Metalloproteinases Contribute Distinct Roles in Neuroendocrine Prostate Carcinogenesis, Metastasis, and Angiogenesis Progression
To evaluate matrix metalloproteinases during metastatic prostatic neuroendocrine cancer development, researchers used transgenic mice expressing SV40 large T antigen in their prostatic neuroendocrine cells, under the control of transcriptional regulatory elements from the mouse cryptdin-2 gene. [Cancer Res]
Targeting Cancer Cell Metabolism: The Combination of Metformin and 2-Deoxyglucose Induces p53-Dependent Apoptosis in Prostate Cancer Cells
In this study, the addition of metformin to 2-deoxyglucose inhibited mitochondrial respiration and glycolysis in prostate cancer cells leading to a severe depletion in ATP. [Cancer Res]
HGF-Induced Invasion by Prostate Tumor Cells Requires Anterograde Lysosome Trafficking and Activity of Na+-H+ Exchangers
Overexpression of the Rab7 effector protein, RILP, resulted in a juxtanuclear location of lysosomes and reduced hepatocyte growth factor (HGF)-induced invasion. Together, these results suggest that the location of lysosomes is an inherently important aspect of invasion by tumor cells. [J Cell Sci]
Oncolytic Herpes Simplex Virus Armed with Xenogeneic Homologue of Prostatic Acid Phosphatase Enhances Antitumor Efficacy in Prostate Cancer
Researchers have examined the expression of a xenogeneic homologue of the prostate cancer antigen, prostatic acid phosphatase (PAP), with the goal of enhancing virotherapy against PAP-expressing tumors. [Gene Ther]
Androgen Ablation Augments Human HLA2.1-Restricted T Cell Responses to PSA Self-Antigen in Transgenic Mice
Researchers sought to investigate whether androgen deprivation would result in circumventing immune tolerance to prostate tumor-associated antigens by impacting CD8 cell responses. [Prostate]
Association of Caveolin-1 and -2 Genetic Variants and Post-Treatment Serum Caveolin-1 with Prostate Cancer Risk and Outcomes
This study evaluated the relationship between post-treatment serum cav-1 levels and single nucleotide polymorphisms (SNPs) in the cav-1 and -2 genes with risk of prostate cancer (PC), aggressive PC, PC recurrence or death. [Prostate]
Identification of a Novel Germline Missense Mutation of the Androgen Receptor in African American Men with Familial Prostate Cancer
Researchers examined the possibility of genomic changes in the androgen receptor in association with familial prostate cancer in African Americans who have a higher incidence and mortality rate and a clinically more aggressive disease presentation than Caucasians. [Asian J Androl]
CLINICAL RESEARCH
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
BRCA2 mutation carriers had an increased risk of prostate cancer and a higher histologic grade, and BRCA1 or BRCA2 mutations were associated with a more aggressive clinical course. [Clin Cancer Res]
Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological Therapeutic
The use of reovirus as a potential treatment modality for prostate cancer has not previously been described, and in this study evidence of in vitro and in vivo activity against prostate cancer was seen both in preclinical models and in six patients. [Cancer Res]
|
|
INDUSTRY NEWS
Roche Needs Boost After Avastin Fails In Prostate Cancer Trial
Roche, a Swiss-based pharmaceutical giant, is starting to lose its lustre as a seemingly fail-save investment. One of its fastest growing drugs, cancer medicine Avastin, tripped up in several trials recently that explored wider use of the medicine. [The Wall Street Journal]
Half a Million for Gene Sequencers
The 10th annual Albany Medical Center Prize, the U.S.’s biggest prize in biomedicine, will go to three scientists who conceptualized the Human Genome Project: Francis Collins, director of the National Institutes of Health; Eric Lander, founding director of the Broad Institute at Harvard and the Massachusetts Institute of Technology; and David Botstein, director of Princeton University’s Lewis-Sigler Institute for Integrative Genomics. [ScienceInsider]
In Annual Rite, Chinese Science Showered with Riches
At the opening session of the National People’s Congress, officials announced that the science and technology budget will rise 8% to 163.3 billion RMB ($24 billion) in 2010. [ScienceInsider]
Novel Gene Expression Test, PROLARIS(TM), Accurately Predicts Prostate Cancer Recurrence
Myriad Genetics, Inc. said data that provides further clinical validation supporting its newest molecular diagnostic product, PROLARIS(TM), was recently presented at the 2010 Genitourinary Cancers Symposium in San Francisco. [Myriad Genetics, Inc. Press Release]
BioSante Pharmaceuticals Closes $18 Million in Registered Direct Offering
BioSante Pharmaceuticals, Inc. announced the closing of the sale, directly to funds affiliated with two institutional investors, of an aggregate of approximately 10.4 million shares of BioSante’s common stock and warrants to purchase up to approximately 5.2 million shares of its common stock, resulting in gross cash proceeds to BioSante of $18 million. [BioSante Pharmaceuticals, Inc. Press Release]
|
|
POLICY NEWS
Request for Information (RFI): To Solicit Input for the National Institute of General Medical Sciences (NIGMS) Strategic Plan for Training and Career Development (NOT-GM-10-102) [National Institutes of Health, United States]
Correction to Required Budget Component for PAR-09-084: Enhancing Developmental Biology Research at Undergraduate Institutions Academic Research Enhancement Award (R15) (NOT-HD-10-007) [National Institutes of Health, United States]
Clarification of Budget Form for PAR-09-092 Academic-Community Partnership Conference Series (U13) (NOT-HD-10-009) [National Institutes of Health, United States]
Recovery Act Limited Competition: The NIH Director’s American Recovery & Reinvestment Act Funded Pathfinder Award to Promote Diversity in the Scientific Workforce (DP4) (RFA-OD-10-013) [National Institutes of Health, United States]
Minority Access to Research Careers Undergraduate Student Training in Academic Research (U-STAR) National Research Service Award (NRSA) Institutional Research Training Grant (T34) (PAR-10-119) [National Institutes of Health, United States]
Strategic Partnering to Evaluate Cancer Signatures [SPECS II] (U01) (PAR-10-126) [National Cancer Institute, United States]
Collaborative Research for Molecular and Genomic Studies of Behavior in Animal Models (R01)
(PA-10-125) [National Institute of General Medical Sciences, United States]
DIA/FDA CDER/CBER Computational Science Annual Meeting, Posted [Food and Drug Administration, United States]
Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; Availability [Food and Drug Administration, United States]
|
|
EVENTS
American Association for Cancer Research (AACR) 101st Annual Meeting
April 17-21, 2010
Washington, DC, United States
American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States
International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States
21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway
United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom
2010 World Cancer Congress
August 18-21, 2010
Beijing, China
Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.
Have we missed an important article or publication in Prostate Cell News? Click here to submit!
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
